Spyre Therapeutics Inc. (SYRE)
NASDAQ: SYRE
· Real-Time Price · USD
16.34
0.16 (0.99%)
At close: Sep 11, 2025, 10:48 AM
0.99% (1D)
| Bid | 16.32 |
| Market Cap | 986.95M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -206.81M |
| EPS (ttm) | -2.53 |
| PE Ratio (ttm) | -6.46 |
| Forward PE | -5.12 |
| Analyst | Buy |
| Ask | 16.38 |
| Volume | 98,427 |
| Avg. Volume (20D) | 550,175 |
| Open | 16.24 |
| Previous Close | 16.18 |
| Day's Range | 16.21 - 16.53 |
| 52-Week Range | 10.91 - 40.26 |
| Beta | 2.88 |
About SYRE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SYRE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SYRE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 months ago
-11.64%
SYRE stock has given up its prior gain. Spyre Ther...
Unlock content with
Pro Subscription
2 months ago
-11.64%
Spyre Therapeutics shares are trading higher after the company announced interim Phase 1 results from its first-in-human trials of SPY002 and SPY072.
2 months ago · seekingalpha.com
Spyre Therapeutics: Positive Anti-TL1A Data Brings 2 Program Pathways ForwardSpyre Therapeutics, Inc.'s SPY002 and SPY072 drug candidates showed strong safety and TL1A inhibition in a phase 1 study, supporting advancement to phase 2 clinical development. SPY002 targets ulcerat...